Citurgia Biochemicals Limited will convene a board meeting on Tuesday, October 6, 2026, to approve the notice for its 51st Annual General Meeting (AGM) for the financial year ending March 31, 2026.

The meeting is scheduled for 4:00 pm at the company's registered office in Mumbai. The agenda includes fixing the date, time, and venue for the upcoming AGM, as well as deciding the period of book closure.

Agenda highlights

The board will consider several key items related to corporate governance and shareholder communication:

• Granting leave of absence to directors, if any
• Fixing the date, time, and venue for the 51st Annual General Meeting
• Approving the notice of the 51st Annual General Meeting
• Approving the Director's Report and applicable annexures for FY26
• Deciding the period of book closure for the 51st Annual General Meeting
• Considering other items with the permission of the chair

Regulatory compliance

The intimation was filed with BSE Limited pursuant to Regulations 29 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document was signed by Kashi Nath, Whole Time Director, on October 1, 2026.

Citurgia Biochemicals Limited has closed its trading window for dealing in company securities effective October 1, 2026. The closure remains in effect until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.

This action is taken in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended by the 2018 amendment regulations. It also adheres to the company's internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons.

Board meeting schedule

The company stated that the specific date of the board meeting for considering and approving the financial results will be intimated in due course. Investors should monitor subsequent filings for this confirmation.

Compliance details

The trading window closure applies to all designated persons within the organization. This standard procedure prevents insider trading during the sensitive period leading up to the release of financial performance data.